The Canadian Biosimilars Forum and Green Shield Canada have publicly commended the government of the province of British Columbia (BC) for announcing that it will implement biosimilar transitioning [1]. Here, patients will transition in a controlled manner from using a reference biological drug to its biosimilar. In their announcement, the Forum believes that BC will make big savings that will allow increased access to existing therapies and faster access to new medicines.
- Home
-
Generics
News
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Research
- Evaluation of pharmaceutical equivalency of manufactured generic drugs in UAE
- New insights into the amount of R & D for new uses of generic drugs
- Pricing and reimbursement of medicines in Canada
- Medicines pricing conditions in Italy and Brazil: comparison of regulations
-
Biosimilars
News
- EMA recommends approval of eculizumab biosimilar Bekemv
- China approves tocilizumab copy biological BAT1806
- FDA accepts application for denosumab biosimilar GP2411
- EMA accepts application for ustekinumab biosimilar AVT04
Research
- Low biosimilar uptake in regions of low social and political trust
- A global overview of manufacturers of follow-on biologicals
- Study supports increased development of insulin biosimilars
- Malaysian hospital pharmacists’ perspective on and role in promoting biosimilars use
- MORE EDITORIAL SECTIONS
- Search
Post your comment